Nov 26,2020 04:27 PM
The commercial papers will mature on January 18, 2021 at an interest rate of 3.68% being offered per annum.
Jubilant Life Sciences Nov 09,2020
|Resolution Type||Description Of Resolution||IiAS Recommendation|
|Name||LTP||PE||Mar Cap||NP Qtr||Div. Yld||Sales Qtr||BV|
|Sun Pharmaceuticals Industries Ltd||547.10||45.38||130,763.76||724.81||0.73||3,207.24||106.10|
|Divis Laboratories Ltd||3,683.55||54.96||96,627.91||513.30||0.44||1,713.78||313.47|
|Dr Reddys Laboratories Ltd||4,882.05||32.84||80,637.51||481.00||0.52||3,333.60||979.45|
|Aurobindo Pharma Ltd||893.00||19.58||52,092.87||801.54||0.34||4,425.43||246.88|
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Jubilant Life Sciences Limited, formerly Jubilant Organosys Limited, is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract... More
Reports by jubilant-life
Dec 03, 2020 01:57 PM
The company’s consolidated revenue stood at Rs2,377.10cr, up 14.96% yoy and 4.74% qoq.
04 Nov 2020
28 Oct 2020
JUBILANT LIFE SCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Com... More
11 Sep 2020
15 Aug 2020
Sub.: Publication of information regarding 42nd Annual General Meeting of the Company to be held on ... More